Pulmonx (LUNG) Projected to Post Earnings on Wednesday

Pulmonx (NASDAQ:LUNG) is anticipated to post its Q4 2025 results before the market opens on Wednesday, February 18th. Analysts expect Pulmonx to post earnings of ($0.39) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 18, 2026 at 4:00 PM ET.

Pulmonx (NASDAQ:LUNG) last released its earnings results on Wednesday, November 12th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.06. Pulmonx had a negative return on equity of 77.58% and a negative net margin of 61.91%.The firm had revenue of $21.50 million for the quarter, compared to the consensus estimate of $20.78 million. On average, analysts expect Pulmonx to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pulmonx Stock Down 5.8%

Shares of NASDAQ:LUNG opened at $1.45 on Wednesday. The company has a current ratio of 4.86, a quick ratio of 4.15 and a debt-to-equity ratio of 0.62. The firm has a market cap of $59.81 million, a price-to-earnings ratio of -1.03 and a beta of 0.07. The stock’s 50-day moving average price is $2.04 and its two-hundred day moving average price is $1.83. Pulmonx has a 12-month low of $1.31 and a 12-month high of $9.37.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on LUNG shares. Wall Street Zen upgraded shares of Pulmonx from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Pulmonx in a research note on Thursday, January 22nd. Lake Street Capital cut their target price on Pulmonx from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, October 28th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $14.00 target price on shares of Pulmonx in a report on Thursday, November 13th. Five equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $6.81.

Institutional Investors Weigh In On Pulmonx

A number of large investors have recently modified their holdings of the stock. Jain Global LLC purchased a new stake in shares of Pulmonx during the 3rd quarter valued at about $30,000. Two Sigma Investments LP grew its position in Pulmonx by 50.3% in the third quarter. Two Sigma Investments LP now owns 46,456 shares of the company’s stock valued at $75,000 after acquiring an additional 15,557 shares in the last quarter. Susquehanna International Group LLP raised its stake in shares of Pulmonx by 34.8% during the third quarter. Susquehanna International Group LLP now owns 67,794 shares of the company’s stock valued at $110,000 after purchasing an additional 17,484 shares during the period. Algert Global LLC raised its stake in shares of Pulmonx by 229.6% during the third quarter. Algert Global LLC now owns 77,722 shares of the company’s stock valued at $126,000 after purchasing an additional 54,142 shares during the period. Finally, XTX Topco Ltd acquired a new position in shares of Pulmonx during the second quarter worth $149,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.